News | July 30, 2008

Abiomed Plans Expanded Impella 2.5 Production in Ireland

July 31, 2008 - Abiomed Inc. said it recently signed a long-term lease for a manufacturing facility in Athlone, Ireland to produce the Impella 2.5 Cardiac Assist Device, which should be in operational in about 18 months.

Abiomed’s Impella 2.5 capacity expansion is intended to meet anticipated long-term demand for the device and augment capacity from the company’s Aachen, Germany facility. In June 2008, Abiomed said it received FDA 510(k) clearance for the Impella 2.5.

The company chose the Ireland location because it was a good building with existing clean room space and a strong supplier network. The Ireland facility has 33,000 square-feet of space, including about 10,000 square-feet of finished clean room space. The company indicated longer-term plans for the Ireland facility to be designated as Abiomed’s global center for high-volume disposable products manufacturing including the Impella 2.5 and the extended Impella product line of the Impella 5.0, right percutaneous and Impella pediatric products and other circulatory care disposable products that Abiomed may offer in the future.

For more information: www.abiomed.com

Related Content

Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
Overlay Init